Jacobio Pharmaceuticals Group Co., Ltd.
DE ˙ DB ˙ KYG4987A1094
€ 0,68 ↑0,02 (2,26%)
2026-09-04
COMPARTILHAR PREÇOS
SecurityDE:77V / Jacobio Pharmaceuticals Group Co., Ltd.
InstitutionECNS - iShares MSCI China Small-Cap ETF
Latest Disclosed Ownership210,600 shares
Latest Disclosed Value $ 166,515
ECNS - iShares MSCI China Small-Cap ETF reports 6.90% decrease in ownership of 77V / Jacobio Pharmaceuticals Group Co., Ltd.

On April 23, 2026 - ECNS - iShares MSCI China Small-Cap ETF filed a NPORT-P form disclosing ownership of 210,600 shares of Jacobio Pharmaceuticals Group Co., Ltd. (DE:77V) valued at $133,731 USD as of February 28, 2026. The entity filed a previous NPORT-P on January 23, 2026 disclosing 226,200 shares of Jacobio Pharmaceuticals Group Co., Ltd.. This represents a change in shares of -6.90% during the quarter. The current value of the position is $143,208 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-23 2026-02-28 NP Jacobio Pharmaceuticals Group EC KYG4987A1094 210,600 -15,600 -6.90 167 -28.45 0.1711
2026-01-23 2025-11-30 NP Jacobio Pharmaceuticals Group EC KYG4987A1094 226,200 54,600 31.82 232 582.35 0.2249
2024-07-26 2024-05-31 NP Jacobio Pharmaceuticals Group EC KYG4987A1094 171,600 -26,400 -13.33 34 -42.37 0.0609
2024-04-24 2024-02-29 NP Jacobio Pharmaceuticals Group EC KYG4987A1094 198,000 -39,600 -16.67 60 -48.70 0.1152
2024-01-26 2023-11-30 NP Jacobio Pharmaceuticals Group EC KYG4987A1094 237,600 26,400 12.50 115 12.75 0.1956
2023-10-27 2023-08-31 NP Jacobio Pharmaceuticals Group EC KYG4987A1094 211,200 39,000 22.65 102 -20.93 0.1660
2023-07-27 2023-05-31 NP Jacobio Pharmaceuticals Group EC KYG4987A1094 172,200 -4,200 -2.38 130 -34.52 0.2199
2023-04-25 2023-02-28 NP Jacobio Pharmaceuticals Group EC KYG4987A1094 176,400 -10,800 -5.77 197 80.73 0.2615
2023-01-25 2022-11-30 NP Jacobio Pharmaceuticals Group EC KYG4987A1094 187,200 43,200 30.00 110 10.10 0.1667
2022-10-25 2022-08-31 NP Jacobio Pharmaceuticals Group EC KYG4987A1094 144,000 144,000 99 0.1791
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.